IN INO Inovio Pharmaceuticals, Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author argues Inovio is attractive into its October 30 PDUFA date because Jupiter Topco acquired a good-sized position in Q2 2026 and its other holdings (ASND, ARGX, LNTH, MIRM) all received FDA approvals. The implied mechanism is that Jupiter Topco's analyst team has a strong regulatory-approval track record, raising the odds INO also gets approved. The catalyst is the PDUFA on 10/30, roughly five weeks out. Main stated risk is implicit: the approval has not yet occurred, and the post offers no clinical data or downside scenario.

The author argues Inovio is undervalued at $1.25-$1.43 versus a projected $3-$7.50, driven by its deep pipeline of cancer and rare-disease DNA-boosting candidates and an upcoming 10/30/26 FDA decision on INO-3107 for recurrent respiratory papillomatosis. The claimed mechanism is that the DNA-boosting technology has broad applicability beyond rare diseases, including as a Covid booster for AstraZeneca's non-RNA spike protein treatment and a Factor VIII protein replacement for hemophilia, plus prospective dMAB and dLNP candidates for Fabry disease and Hypophosphatasia. Supporting catalysts include Phase I/II data showing 72% of patients had at least a 50% reduction in repeat surgeries in year one and 86% in year two, and the ApolloBio China partnership for VGX-3100 in HSIL, which met preannounced targets. The main stated risks are that the FDA has questioned accelerated-approval eligibility and Inovio may need a confirmatory trial of roughly 100 patients, with cash runway extended only into early 2027 after raising $18.3 million.